Prognostic Value and Clinical Predictors of Lymph Node Metastases in Pancreatic Neuroendocrine Tumors
- PMID: 32132507
- DOI: 10.1097/MPA.0000000000001493
Prognostic Value and Clinical Predictors of Lymph Node Metastases in Pancreatic Neuroendocrine Tumors
Abstract
Objectives: To investigate the correlation between lymph node metastasis (LNM) and various clinicopathological features of pancreatic neuroendocrine tumors (pNETs) and its impact on prognosis.
Methods: We searched the Surveillance Epidemiology and End Results database (2004-2015) for patients with surgically treated pNETs. Factors correlated with LNMs were analyzed by logistic regression and by Cox analysis.
Results: For tumors of 1 to 4 cm, age (P < 0.001, P = 0.014), grade (P < 0.001, P < 0.001), LNMs (P = 0.008, P < 0.001), and size (P = 0.038, P = 0.002) predicted overall survival (OS) and disease-specific survival (DSS). For tumor greater than 4 cm, age (P < 0.001, P = 0.001) and grade (P = 0.011, P = 0.048) were independent prognostic factors of OS and DSS. Lymph node metastasis modestly predicted DSS (P = 0.028) but not OS (P = 0.218).
Conclusions: In pNETs greater than 4 cm, LNM is not a predictor of OS and modestly predicts DSS, and lymphadenectomy may be unhelpful in these patients. For pNETs 1 to 4 cm, LNM predicts poor OS and DSS, which supports lymphadenectomy in these patients. Pancreas-sparing resection with only limited peripancreatic node sampling needs to be questioned.
Similar articles
-
Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Pancreatic Neuroendocrine Tumors Confined To and Extending Beyond the Pancreas.J Gastrointest Surg. 2016 Dec;20(12):1966-1974. doi: 10.1007/s11605-016-3243-7. Epub 2016 Oct 6. J Gastrointest Surg. 2016. PMID: 27714644
-
Importance of lymph node involvement in pancreatic neuroendocrine tumors: impact on survival and implications for surgical resection.J Gastrointest Surg. 2015 Jan;19(1):152-60; discussion 160. doi: 10.1007/s11605-014-2624-z. Epub 2014 Aug 14. J Gastrointest Surg. 2015. PMID: 25118642
-
Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.Pancreas. 2012 Aug;41(6):840-4. doi: 10.1097/MPA.0b013e31823cdaa0. Pancreas. 2012. PMID: 22781907
-
What Is the Role of Lymph Node Resections in Small Islet Tumors?Adv Surg. 2023 Sep;57(1):47-58. doi: 10.1016/j.yasu.2023.06.001. Adv Surg. 2023. PMID: 37536861 Review.
-
Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors.Ann Surg Oncol. 2021 Mar;28(3):1614-1624. doi: 10.1245/s10434-020-08850-7. Epub 2020 Jul 27. Ann Surg Oncol. 2021. PMID: 32720049
Cited by
-
Enucleation Is a Feasible Procedure for Well-Differentiated pNEN-A Matched Pair Analysis.Cancers (Basel). 2022 May 23;14(10):2570. doi: 10.3390/cancers14102570. Cancers (Basel). 2022. PMID: 35626174 Free PMC article.
-
Head and body/tail pancreatic neuroendocrine tumors have different biological characteristics and clinical outcomes.J Cancer Res Clin Oncol. 2020 Nov;146(11):3049-3061. doi: 10.1007/s00432-020-03303-w. Epub 2020 Jun 29. J Cancer Res Clin Oncol. 2020. PMID: 32601815 Free PMC article.
-
Hyperglycemia is associated with adverse prognosis in patients with pancreatic neuroendocrine neoplasms.Endocrine. 2022 Aug;77(2):262-271. doi: 10.1007/s12020-022-03100-0. Epub 2022 Jul 5. Endocrine. 2022. PMID: 35790660
-
Evaluation of Risk Factors for Distant and Lymph Node Metastasis of Pancreatic Neuroendocrine Tumors.Ther Clin Risk Manag. 2022 Jul 29;18:745-752. doi: 10.2147/TCRM.S361332. eCollection 2022. Ther Clin Risk Manag. 2022. PMID: 35937972 Free PMC article.
-
What Are the Place and Modalities of Surgical Management for Pancreatic Neuroendocrine Neoplasms? A Narrative Review.Cancers (Basel). 2021 Nov 26;13(23):5954. doi: 10.3390/cancers13235954. Cancers (Basel). 2021. PMID: 34885063 Free PMC article. Review.
References
-
- Halfdanarson TR, Rabe KG, Rubin J, et al. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19:1727–1733.
-
- Falconi M, Plockinger U, Kwekkeboom DJ, et al. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology. 2006;84:196–211.
-
- Ellison TA, Wolfgang CL, Shi C, et al. A single institution's 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram. Ann Surg. 2014;259:204–212.
-
- Fesinmeyer MD, Austin MA, Li CI, et al. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1766–1773.
-
- Bilimoria KY, Talamonti MS, Tomlinson JS, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg. 2008;247:490–500.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical